Login to Your Account



HGS Gains Exclusive License From Abgenix For CCR5 MAb

By Brady Huggett


Tuesday, May 13, 2003
Human Genome Sciences Inc. exclusively licensed rights from Abgenix Inc. to develop a fully human monoclonal antibody to the CCR5 receptor, for which Abgenix earns an undisclosed milestone payment. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription